{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:14:06Z","timestamp":1789913646777,"version":"4.0.1"},"reference-count":64,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"paper was not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2019,3,4]]},"DOI":"10.1080\/17512433.2019.1568868","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T15:04:55Z","timestamp":1547478295000},"page":"179-187","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Acalabrutinib for adults with mantle cell lymphoma"],"prefix":"10.1080","volume":"12","author":[{"given":"Wojciech","family":"Jurczak","sequence":"first","affiliation":[{"name":"Department of Hematology, Jagiellonian University, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-4125","authenticated-orcid":false,"given":"Monika","family":"D\u0142ugosz-Danecka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jagiellonian University, Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,1,26]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"issue":"10044","key":"cit0006","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine O","year":"2016","journal-title":"Lancet"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"issue":"2","key":"cit0009","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","volume":"150","author":"Romaguera JE","year":"2010","journal-title":"Br J Haematol"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13456"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00559-8"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141018"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0807082"},{"issue":"2","key":"cit0017","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4049\/jimmunol.152.2.557","volume":"152","author":"Smith CI","year":"1994","journal-title":"J Immunol"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.1046"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1257795"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14324"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0250-9"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0313-y"},{"key":"cit0028","doi-asserted-by":"crossref","unstructured":"Li N, Sun Z, Liu Y, et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton\u2019s tyrosine kinase (BTK) inhibitor. Cancer Res. 2015;75(15 Supplement):2597.","DOI":"10.1158\/1538-7445.AM2015-2597"},{"key":"cit0029","doi-asserted-by":"crossref","unstructured":"Tam C, Grigg AP, Opat S, et al. The BTK inhibitor, Bgb-3111, Is Safe, tolerable, and highly active in patients with relapsed\/refractory B-cell malignancies: initial report of a Phase 1 first-in-human trial. Blood. 2015;126(23):832.","DOI":"10.1182\/blood.V126.23.832.832"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664086"},{"key":"cit0031","doi-asserted-by":"crossref","unstructured":"Binnerts ME, Otipoby KL, Hopkins BT, et al. Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation. Mol Cancer Ther. 2015;14(12 Supplement 2):C186.","DOI":"10.1158\/1535-7163.TARG-15-C186"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203489"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.140806"},{"key":"cit0034","author":"Lee-Verges E","year":"2018","journal-title":"Int J Cancer"},{"key":"cit0035","doi-asserted-by":"crossref","unstructured":"Reiff SD, Mantel R, Smith LL, et al. The Bruton\u2019s tyrosine kinase (BTK) inhibitor ARQ 531 effectively inhibits wild type and C481S mutant BTK and is superior to ibrutinib in a mouse model of chronic lymphocytic leukemia. Blood. 2016;128(22):3232.","DOI":"10.1182\/blood.V128.22.3232.3232"},{"issue":"1","key":"cit0036","first-page":"2778","volume":"130","author":"Jurczak W","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0463"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1506327"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1446"},{"key":"cit0041","doi-asserted-by":"crossref","unstructured":"Gardner HL, Harrington BK, Izumi R, et al. Abstract 1744: ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma. Cancer Res. 2014;74(19 Supplement):1744.","DOI":"10.1158\/1538-7445.AM2014-1744"},{"key":"cit0042","doi-asserted-by":"crossref","unstructured":"Niemann CU, Montraveta A, Herman SEM, et al. Abstract 2624: the novel Bruton\u2019s tyrosine kinase inhibitor ACP-196 shows in vivo efficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model. Cancer Res. 2014;74(19 Supplement):2624.","DOI":"10.1158\/1538-7445.AM2014-2624"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2708-9"},{"key":"cit0044","volume":"130","author":"Covey T","year":"2017","journal-title":"Blood"},{"key":"cit0045","first-page":"498","volume-title":"Oral abstract #498: ASH 59th Annual Meeting and Exposition, Atlanta (GA). Blood (abstract book)130","author":"Byrd JC","year":"2017"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0650"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(16)32699-5"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.32"},{"key":"cit0055","doi-asserted-by":"crossref","unstructured":"Overman MJ, Lopez CD, Benson AB, et al. A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC). J Clin Oncol. 2016;34(15_suppl):4130.","DOI":"10.1200\/JCO.2016.34.15_suppl.4130"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7521"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.638.638"},{"issue":"16","key":"cit0061","first-page":"1594","volume":"374","author":"Burger JA","year":"2016","journal-title":"N Engl J Med"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.016"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115179"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2019.1568868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T01:53:36Z","timestamp":1720922016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2019.1568868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,26]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3,4]]}},"alternative-id":["10.1080\/17512433.2019.1568868"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2019.1568868","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}